Core Viewpoint - The company held its sixth board meeting on July 31, 2025, where several key resolutions were passed, including the reappointment of the auditing firm and the signing of an investment agreement for a new project [1][2][3]. Group 1: Audit and Governance - The board approved the reappointment of Rongcheng Accounting Firm for the 2025 annual audit, with the management authorized to negotiate the audit fees based on various factors [1][2]. - The board proposed to increase the number of board members from 7 to 8, adding one employee representative director while maintaining the number of independent directors at 3 [3][4]. - The board also approved the formulation and revision of several corporate governance systems, which will be submitted for shareholder approval [4]. Group 2: Project Investment - The board agreed to sign an investment cooperation agreement with the Huainan Economic and Technological Development Zone Management Committee for a high-end auxiliary material manufacturing base project [2][3]. - This investment agreement will also require shareholder approval at the upcoming extraordinary general meeting [2][3]. Group 3: Shareholder Meeting - The board scheduled the 2025 first extraordinary general meeting for August 18, 2025, to review the resolutions passed during the board meeting [4].

Core Viewpoint - The company announced the approval of the proposal to reappoint the auditing firm for the fiscal year 2025 during the sixth meeting of the sixth supervisory board [2] Group 1 - The sixth supervisory board meeting of the company took place on July 31 [2] - The proposal regarding the reappointment of the auditing institution was among the key items discussed and approved [2]

（文章来源：证券日报） 证券日报网讯 7月31日晚间，山河药辅发布公告称，公司第六届董事会第六次会议审议通过了《关于续 聘2025年度审计机构的议案》等多项议案。 ...

Core Viewpoint - The company, Shanhe Pharmaceutical Auxiliary (300452), announced that it will hold its first extraordinary general meeting of shareholders for 2025 on August 18, 2025, to review the proposal for the reappointment of the auditing institution for the fiscal year 2025 [1] Group 1 - The extraordinary general meeting is scheduled for August 18, 2025 [1] - The agenda includes the review of the proposal regarding the reappointment of the auditing institution for the year 2025 [1]

Core Viewpoint - The company announced the reappointment of Rongcheng Accounting Firm as its auditor for the 2025 annual report and internal control audit, with a one-year term [1] Group 1 - The sixth meeting of the sixth board of directors and the sixth meeting of the sixth supervisory board were held on July 31, 2025 [1] - The proposal to reappoint the accounting firm was approved and will be submitted to the first extraordinary shareholders' meeting of 2025 for review [1]

格隆汇7月31日丨山河药辅(300452.SZ)公布，公司与淮南经济技术开发区管理委员会（简称"淮南经开 区管委会"）经友好协商，双方就公司在淮南经开化工园区投资建设高端辅料智造基地的相关事项达成 合作共识，拟签署高端辅料智造基地项目投资协议书。项目用地约200亩，总投资10.5亿元人民币，其 中固定资产投资6亿元人民币。项目分两期建设，其中本期项目用地约100亩，总投资4.5亿元人民币， 固定资产投资3亿元人民币，后期预留项目用地约100亩，总投资6亿元人民币，固定资产投资3亿元人民 币。项目内容：高端辅料智能生产线及质检、环保辅助设施等。 ...

Core Points - The company, Shanhe Pharmaceutical Auxiliary (300452.SZ), has reached a cooperation consensus with the Huainan Economic and Technological Development Zone Management Committee to invest in a high-end auxiliary material manufacturing base in the Huainan Chemical Park [1] - The project will cover an area of approximately 200 acres with a total investment of 1.05 billion RMB, including a fixed asset investment of 600 million RMB [1] - The project will be constructed in two phases, with the first phase covering about 100 acres and a total investment of 450 million RMB, including a fixed asset investment of 300 million RMB [1] - The second phase will reserve another 100 acres with a total investment of 600 million RMB and a fixed asset investment of 300 million RMB [1] - The project will include high-end auxiliary material intelligent production lines and quality inspection, as well as environmental protection auxiliary facilities [1]

Group 1 - The company, Shanhe Pharmaceutical Auxiliary, announced a collaboration with the Huainan Economic and Technological Development Zone Management Committee to invest in a high-end auxiliary material manufacturing base in the Huainan Chemical Park [2] - The project involves re-planning the remaining land from the company's new pharmaceutical auxiliary material production base project, which was previously announced [2] - The acquisition of land use rights is subject to uncertainty regarding the bidding, auction, or listing process, as well as the final transaction price and timing [2] Group 2 - For the year 2024, the company's revenue composition is entirely from the pharmaceutical manufacturing industry, with a 100% share [3]

安徽山河药用辅料股份有限公司 年报信息披露重大差错责任追究制度 第一章 总 则 则》、中国证监会关于财务报告信息披露的相关规定以及中国证监会和深圳 证券交易所发布的有关年报信息披露指引、准则、通知等，使年报信息披露发生 重大差错或不良影响的； 第二条 公司有关人员应当严格执行《企业会计准则》及相关规定，严格遵 守公司与财务报告相关的内部控制制度，确保财务报告真实、公允地反映公司的 财务状况、经营成果和现金流量。公司有关人员不得干扰、阻碍审计机构及相关 注册会计师独立、客观地进行年报审计工作。 第三条 公司董事、高级管理人员以及与年报信息披露相关的其他人员在年 报信息披露工作中违反国家有关法律、法规、规范性文件以及公司规章制度，未 勤勉尽责或者不履行职责，导致年报信息披露发生重大差错，应当按照本制度的 规定追究其责任。 第四条 本制度所指年报信息披露重大差错包括年度财务报告存在重大会计 差错、其他年报信息披露存在重大错误或重大遗漏、业绩预告或业绩快报存在重 大差异等情形。具体包括以下情形: 1、违反《公司法》、《证券法》、《企业会计准则》和《企业会计制度》 等国家法律法规的规定，使年报信息披露发生重大差错或造成 ...

安徽山河药用辅料股份有限公司 董事会战略与投资委员会工作细则 第一章 总 则 第一条 为适应安徽山河药用辅料股份有限公司（以下简称"公司"）战略 发展需要，增强公司核心竞争力，确定公司发展规划，健全投资决策程序，加强 决策科学性，提高重大投资决策的效益和决策的质量，完善公司治理结构，根据 《中华人民共和国公司法》、《上市公司治理准则》、《安徽山河药用辅料股份有限 公司公司章程》（以下简称"《公司章程》"）及其他有关规定，公司特设立董事会 战略与投资委员会，并制定本工作细则。 第二条 战略与投资委员会是董事会下设的专门委员会，主要负责对公司长 期发展战略和重大投资决策进行研究并向董事会提出建议。 第七条 战略与投资委员会的主要职责权限： （一）对公司长期发展战略规划进行研究并提出建议； （二）对《公司章程》规定须经董事会批准的重大投资融资方案进行研究并 提出建议； （三）对《公司章程》规定须经董事会批准的重大资本运作、资产经营项目 第二章 人员组成 第三条 战略与投资委员会由 3 名董事组成，其中包括 1 名独立董事。 第四条 战略与投资委员会由董事长、二分之一以上独立董事或者全体董事 的三分之一提名，并由董事 ...